[go: up one dir, main page]

CR9705A - Composiciones farmaceuticas de liberacion sostenida y procesos de las mismas - Google Patents

Composiciones farmaceuticas de liberacion sostenida y procesos de las mismas

Info

Publication number
CR9705A
CR9705A CR9705A CR9705A CR9705A CR 9705 A CR9705 A CR 9705A CR 9705 A CR9705 A CR 9705A CR 9705 A CR9705 A CR 9705A CR 9705 A CR9705 A CR 9705A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
processes
same
sustained release
sustained liberation
Prior art date
Application number
CR9705A
Other languages
English (en)
Inventor
Jain Rajesh
Chand Jindal Kour
Singh Sukhjeet
Boldhane Sanjay
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9705(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CR9705A publication Critical patent/CR9705A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmaceuticas de liberacion sostenida novedosas que comprenden al menos un o unos ingredientes activos, o sus formas tautomericas, analogos, isomeros, polimorfos, solvatos o sales de los mismos; preferiblemente se suministra un agente activo antiviral. Tambien se provee un proceso de preparacion de tal composicion y el metodo para su utilizacion. Las composiciones de liberacion sostenida de la presente invencion son capaces de liberar el agente activo en una forma deseada por un periodo extendido de tiempo.
CR9705A 2005-06-29 2008-01-29 Composiciones farmaceuticas de liberacion sostenida y procesos de las mismas CR9705A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1680DE2005 2005-06-29

Publications (1)

Publication Number Publication Date
CR9705A true CR9705A (es) 2008-10-30

Family

ID=37027780

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9705A CR9705A (es) 2005-06-29 2008-01-29 Composiciones farmaceuticas de liberacion sostenida y procesos de las mismas

Country Status (15)

Country Link
US (1) US20090099154A1 (es)
EP (1) EP1912628A2 (es)
JP (1) JP2009500318A (es)
CN (1) CN101212957A (es)
AR (1) AR055070A1 (es)
AU (1) AU2006263338A1 (es)
BR (1) BRPI0613070A2 (es)
CA (1) CA2613407A1 (es)
CR (1) CR9705A (es)
EA (1) EA200800162A1 (es)
MX (1) MX2008000084A (es)
NO (1) NO20080399L (es)
RS (1) RS20070512A (es)
TN (1) TNSN07490A1 (es)
WO (1) WO2007000779A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2428205T3 (da) 2006-03-16 2012-10-22 Tris Pharma Inc Modificerede formuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
MX2008015571A (es) * 2006-06-08 2009-04-24 Univ Yale Metodo de destilado de columna de etapa multiple (mscd) para recuperacion de una sustancia disuelta osmotica.
EP2101743B1 (en) * 2006-12-15 2010-06-23 Campina Nederland Holding B.V. Extended release excipient and its use
EP1935411A1 (en) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
MX2009007913A (es) * 2007-01-25 2009-07-31 Panacea Biotec Ltd Composicion farmaceutica de liberacion modificada y un procedimiento para elaborarla.
HUE028598T2 (en) 2007-06-08 2016-12-28 Boehringer Ingelheim Int Extended release nevirapine preparation
MY147827A (en) * 2007-10-19 2013-01-31 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
RU2607595C2 (ru) * 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
WO2011117875A1 (en) * 2010-03-26 2011-09-29 Hetero Research Foundation Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium
KR20120055313A (ko) * 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
CN102058553B (zh) * 2010-12-28 2012-10-10 哈药集团三精制药股份有限公司 阿昔洛韦缓释片及其制备方法
CA2847614C (en) 2011-09-30 2018-10-23 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
FR2983409B1 (fr) 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
JP2013119540A (ja) * 2011-12-08 2013-06-17 Nipro Corp 固形医薬組成物およびその製造法
AU2013235345B2 (en) 2012-03-21 2016-03-24 Galleon Labs Llc Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
WO2014181390A1 (ja) * 2013-05-08 2014-11-13 全星薬品工業株式会社 機能性高分子皮膜で被覆された高含量薬物粒子およびそれを含む錠剤ならびにそれらの製造方法
US20160193182A1 (en) * 2013-08-14 2016-07-07 Evonik Roehm Gmbh Coating composition
US20160250253A1 (en) * 2013-09-24 2016-09-01 Cosmederm Bioscience, Inc. Strontium-containing complexes for treating gastroesophageal reflux and barrett's esophagus
CN103705933A (zh) * 2013-12-18 2014-04-09 北京科源创欣科技有限公司 奥卡西平药物组合物及制备方法
JP6532765B2 (ja) * 2014-06-06 2019-06-19 株式会社ファンケル 即効性成分と持続性成分を含む錠剤
US10111838B2 (en) * 2014-11-26 2018-10-30 Evonik Roehm Gmbh Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
CN104666267B (zh) * 2015-03-27 2017-08-08 康普药业股份有限公司 一种阿昔洛韦药物组合物
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
KR102329377B1 (ko) * 2017-02-03 2021-11-19 가부시키가이샤 도요 신야쿠 고형 제제
CN106943356B (zh) * 2017-05-10 2019-11-08 武汉人福药业有限责任公司 一种泛昔洛韦缓释颗粒剂及其制备方法
JP6958856B2 (ja) * 2017-08-09 2021-11-02 日本臓器製薬株式会社 錠剤
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
CN109466152B (zh) * 2018-09-04 2021-01-26 浙江罗奇泰克科技股份有限公司 一种高导热铁基板的制作方法
EP4271380A4 (en) * 2020-12-29 2025-01-22 Abbvie Inc. UPADACITINIB EXTENDED RELEASE FORMULATIONS
WO2024176162A1 (en) * 2023-02-22 2024-08-29 Sun Pharmaceutical Industries Limited Stable pharmaceutical composition of histamine h2‐receptor antagonist

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE77165B1 (en) * 1991-01-30 1997-12-03 Wellcome Found Water-dispersible tablet containing acyclovir
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US20030134864A1 (en) * 1996-02-07 2003-07-17 Smithkline Beecham P.L.C. Activity of penciclovir against epstein-barr virus
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
MXPA01002634A (es) * 1998-09-14 2002-06-04 Ranbaxy Lab Ltd Sistema de entrega que controla a una droga oralmente administrada proporcionando control en tiempo y espacial.
WO2002102415A1 (en) * 2001-06-18 2002-12-27 Blue Cross Laboratories Limited Gastric floating system
AU2003255871A1 (en) * 2002-08-14 2004-03-03 Ranbaxy Laboratories Limited Extended release matrix tablets
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery

Also Published As

Publication number Publication date
WO2007000779A2 (en) 2007-01-04
MX2008000084A (es) 2008-03-18
CN101212957A (zh) 2008-07-02
US20090099154A1 (en) 2009-04-16
BRPI0613070A2 (pt) 2010-12-21
JP2009500318A (ja) 2009-01-08
AU2006263338A1 (en) 2007-01-04
EA200800162A1 (ru) 2008-06-30
AR055070A1 (es) 2007-08-01
NO20080399L (no) 2008-03-31
CA2613407A1 (en) 2007-01-04
EP1912628A2 (en) 2008-04-23
RS20070512A (sr) 2009-01-22
TNSN07490A1 (en) 2009-03-17
AU2006263338A2 (en) 2008-06-05
WO2007000779A3 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
CR9705A (es) Composiciones farmaceuticas de liberacion sostenida y procesos de las mismas
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
CR10549A (es) Composicion farmaceutica que contienen un acido tetrahidrofolico
ECSP077268A (es) Polimorfo ii de rapamicina y los usos de los mismos
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
HN2012001162A (es) Triazolopiridinas
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY33622A (es) Isoxazolín oximas como agentes antiparasitarios
UY27446A1 (es) Nuevos compuestos
DOP2010000084A (es) Derivado de uracilo o timina para el tratamiento de hepatitis c
NI200300042A (es) Compuestos que modulan la actividad de ppar y metodos para su preparacion.
UY30327A1 (es) Nuevos compuestos ii
AR050946A1 (es) Composiciones para el tratamiento de la ropa.
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
SV2003001089A (es) Agentes antibacterianos pc20512
MX378653B (es) Composicion limpiadora auto-espumante para enjuagar que contiene ivermectina.
ECSP077262A (es) Composicion antihistaminica
AR038618A1 (es) Forma poliformica cristalina de clorhidratos de irinotecan
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
PA8589801A1 (es) Aminoalcoxiindoles
GT200600025A (es) Pirazolopiridinas y sales de las mismas, una composicion farmaceutica que comprende dichos compuestos, un metodo para prepararlos y su uso
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
GT200900310A (es) Macrociclos y sus usos
UY29821A1 (es) Derivados de 5,6-dihidropirazolo(3,4)(1,4)diazepin-4(1h)-ona, procesos de preparación de dichos derivados, composiciones farmacéuticas conteniéndolos y aplicaciones.
DOP2002000386A (es) Agentes antibacterianos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)